Research programme: anti-TrkA monoclonal antibodies - Glenmark Pharmaceuticals

Drug Profile

Research programme: anti-TrkA monoclonal antibodies - Glenmark Pharmaceuticals

Latest Information Update: 10 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lay Line Genomics
  • Developer Glenmark Pharmaceuticals S.A.
  • Class Monoclonal antibodies
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 04 Jun 2014 A lead candidate from this programme has entered clinical development
  • 04 Feb 2013 Preclinical trials in Pain in Switzerland (Parenteral)
  • 25 May 2011 Preclinical development is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top